Conference Roundup

Significant reductions in medication use observed in patients with ALGS treated with maralixibat

Treatment with maralixibat significantly reduces the need for multiple concomitant medications in patients with Alagille syndrome (ALGS), particularly for managing cholestatic pruritus, according to a study presented at ESPGHAN 2024. The study, conducted by Mirum Pharmaceuticals, utilized pharmacy data from the Mirum Access Plus program to evaluate trends in concomitant...